The impact of levodopa‐carbidopa intestinal gel on health‐related quality of life in Parkinson's disease.

Trial Profile

The impact of levodopa‐carbidopa intestinal gel on health‐related quality of life in Parkinson's disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2015

At a glance

  • Drugs Levodopa/carbidopa (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Aug 2015 New trial record
    • 18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top